Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.

中文翻译：

---

vutrisiran 对转甲状腺素蛋白淀粉样变性伴心肌病的益处


来自 HELIOS-B 试验的数据表明，对 vutrisiran 的 RNA 干扰可降低转甲状腺素蛋白淀粉样变性伴心肌病患者的死亡和复发心血管事件的风险。